期刊文献+

Her2和Met蛋白在肺腺癌中的表达及意义

下载PDF
导出
摘要 目的探讨表皮生长因子受体2(Her2)和间质表皮转化因子(Met)在肺腺癌中的表达及意义。方法应用免疫组化法检测Her2与Met在肺腺癌(40例)、癌旁组织(36例)及正常肺组织(20例)中的表达,分析表达情况与肺腺癌临床病理特征间的关系。结果 Her2与Met在正常肺组织表达低或无表达;Met在癌旁组织阳性表达率高于正常肺组织(P<0.05);两者在肺腺癌表达增高,以阳性及强阳性表达为主(P<0.05);两者表达与年龄、性别、吸烟史、肿瘤大小、TNM分级、分化程度无相关,但与淋巴结转移相关。两者在肺腺癌组织中的表达呈正相关(r=0.83,P<0.05)。结论 Her2与Met的表达水平可反映肺腺癌的淋巴结转移倾向,在靶向治疗前检测肺腺癌Her2和Met的表达,将对耐药和淋巴结转移的预测有指导作用。
出处 《广东医学》 CAS 北大核心 2015年第9期1396-1399,共4页 Guangdong Medical Journal
基金 广东省自然科学基金资助项目(编号:S2012010008555)
  • 相关文献

参考文献15

  • 1GABRIELSON E.Worldwide trends in lung cancer pathology[J].Respirology,2006,11(5);533-538.
  • 2KWAK E.The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer[J].Oncologist,2011,16(11):1498-1507.
  • 3ENGELMAN J A,ZEJNULLAHU K,MITSUDOMI T,et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J].Science,2007,316(5827);1039-1043.
  • 4DE1TERBECK F Ct BOFFA D J,TANOUE L T.The new lung cancer staging system[J].Chest,2009,136(1):260-271.
  • 5杨欣,薛丽燕,郭蕾,温芃,林冬梅.多种肿瘤标志物在肺腺癌中的表达及预后意义的研究[J].中国肺癌杂志,2014,17(3):243-253. 被引量:16
  • 6NAKAMURA Y,NIKI T,GOTO A,et al.c-Met activation in lung adenocarcinoma tissues:An immunohistochemical analysis[J].Cancer Sci,2007,7(98):1006-1013.
  • 7CAPPUZZO F,VARELLA GARCIA M,SHIGEMATSU H,et al.Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients[J].J Clin Oncol,2005,23(22):5007-5018.
  • 8ENGELMAN J A,CANTLEY L C.The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors[J].Clin Cancer Res,2006,12(14 Pt 2):4372s-4376s.
  • 9MAR N,VREDENBURGH J J,WASSER J S.Targeting HER2 in the treatment of non-small cell lung cancer[J].Lung Cancer,2015,87(3):220-225.
  • 10TULASNE D,FOVEAU B.The shadow of death on the MET tyrosine kinase receptor[J].Cell Death Differ,2008,15(3):427-434.

二级参考文献20

  • 1Gabrielson E. Worldwide trends in lung cancer pathology. Respirology, 2006, 11(5): 533-538.
  • 2Jemal A, Ward E, Thnn M. Declining death rates reflect progress against cancer. PLoS One, 2010, 5(3): e9584.
  • 3Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokers-- a review. EurJ Cancer, 2012, 48(9): 1299-1311.
  • 4Strauss GM, Kwiatkowski DJ, Harpole DH, et al. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol, 1995, 13(5): 1265-1279.
  • 5Anagnostou VK, Syrigos KN, Bepler G, et al. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol, 2009, 27(2): 271-278.
  • 6Kadota K, Nitadori J, Sarkaria IS, et al. Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer, 2013, 119(5): 931-938.
  • 7Lee JG, Kim S, Shim HS. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung. Lung Cancer, 2012, 77(1): 156-161.
  • 8Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res, 2002, 62(7): 2141-2150.
  • 9Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res, 2005, 11 (14): 5084-5089.
  • 10Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res, 2005, 11 (20): 7280-7287.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部